— Amicus Therapeutics (NASDAQ: FOLD) reported Q3 2019 loss of $0.24 per share, vs. a loss of $0.32 expected.
— Revenues grew 137% to $48.8 million, vs. $47.6 million expected.
— Global revenue for Galafold was $48.8 million.
— FY19 Galafold revenue is expected to be $170 million to $180 million.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
KinderCare Learning Companies to offer 24 Mln shares for $23-27 in US IPO
In 2024, the IPO market shifted to recovery mode, with a significant increase in activity compared to last year when it witnessed a slowdown. Encouraged by the booming stock market
Constellation Brands’ (STZ) beer business remains resilient in a tough environment
Shares of Constellation Brands, Inc. (NYSE: STZ) gained 1% on Friday. The stock has dropped 4% over the past three months. The beverages giant delivered better-than-expected earnings results for the
What to look for when Charles Schwab (SCHW) reports Q3 2024 results
Financial services company The Charles Schwab Corporation (NYSE: SCHW) is preparing to report third-quarter results on October 14, with experts predicting a mixed outcome. As part of its long-term succession
